http://www.forbes.com/sites/davidshaywitz/ en-usDavid ShaywitzDavid Shaywitz's stories.Copyright 2019 Forbes LLChttps://secure.gravatar.com/avatar/8445b895fe26bbe2aa09333420e04797?s=400&d=mm&r=gDavid Shaywitzhttps://www.forbes.com/sites/davidshaywitz/feed/ https://www.forbes.com/sites/davidshaywitz/2019/10/27/captivating-moonrise-podcast-series-highlights-role-of-narrative-in-technology-adoption/ Captivating Moonrise Podcast Series Highlights Role Of Narrative In Technology AdoptionPowerful evolving narratives inspire, inform, reflect, and define all our activities, particularly efforts to introduce emerging technologies into established organizations; entrepreneurs must recognize, engage, and at times originate and advance such narratives, or risk being consumed by them.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5db636aa70088a0006a9aafbMon, 28 Oct 2019 00:30:34 +00002019-10-28T00:30:34ZPowerful evolving narratives inspire, inform, reflect, and define all our activities, particularly efforts to introduce emerging technologies into established organizations; entrepreneurs must recognize, engage, and at times originate and advance such narratives, or risk being consumed by them.https://www.forbes.com/sites/davidshaywitz/2019/10/16/getting-beyond-hype-vs-hope-in-precision-medicine-and-ai-the-life-cycle-of-technology-revolutions/ Understanding Precision Medicine And AI Within The Life Cycle Of Technology RevolutionsTechnology transformations tend to follow a well-described pattern. Debates around successive emerging healthcare technologies – precision medicine, AI – are just the most recent iterations of the discussions that have surrounded the introduction of every new and potentially important technology. David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5da757c64bbc2d000693dbe6Wed, 16 Oct 2019 18:18:48 +00002019-10-16T18:18:48ZTechnology transformations tend to follow a well-described pattern. Debates around successive emerging healthcare technologies – precision medicine, AI – are just the most recent iterations of the discussions that have surrounded the introduction of every new and potentially important technology. https://www.forbes.com/sites/davidshaywitz/2019/10/10/are-healthcare-enterprises-buying-silicon-valleys-evangelistic-sell/ Are Healthcare Enterprises Buying Silicon Valley’s Evangelistic Sell?Silicon Valley's "fake it 'til you make it" ethos is championed as "the evangelistic sale." Success requires the right customers -- are they out there? David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5d9fe41eaa8275000770b977Fri, 11 Oct 2019 02:46:25 +00002019-10-11T02:46:25ZSilicon Valley's "fake it 'til you make it" ethos is championed as "the evangelistic sale." Success requires the right customers -- are they out there? https://www.forbes.com/sites/davidshaywitz/2019/09/12/the-digital-dozen-my-12-takeaways-for-hbs-on-data-dna-and-pharma/ The Digital Dozen: My 12 Takeaways for HBS On Data, DNA, And PharmaAs a physician, scientist, technologist, drug developer, investor, I’ve accumulated my share of experience+perspective, which I recently had the chance to distill+share as a guest on a new podcast series out of Harvard Business School. Here are my 12 take-aways on data, digital, DNA, and pharma.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5d74668dcacaf6008590305eThu, 12 Sep 2019 21:53:00 +00002019-09-12T21:53:00ZAs a physician, scientist, technologist, drug developer, investor, I’ve accumulated my share of experience+perspective, which I recently had the chance to distill+share as a guest on a new podcast series out of Harvard Business School. Here are my 12 take-aways on data, digital, DNA, and pharma.https://www.forbes.com/sites/davidshaywitz/2019/08/29/engineering-as-translation-what-biomedical-entrepreneurs-can-learn-from-a-petrol-ceo/ Engineering As Translation: What Biomedical Entrepreneurs Can Learn From A Petrol CEOIn his latest book, engineer and former BP CEO John Browne addresses several themes related to technology and translational that are likely of particular interest to biomedical entrepreneurs.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5d683ae51c7c400086584a38Thu, 29 Aug 2019 23:36:00 +00002019-08-29T23:36:00ZIn his latest book, engineer and former BP CEO John Browne addresses several themes related to technology and translational that are likely of particular interest to biomedical entrepreneurs.https://www.forbes.com/sites/davidshaywitz/2019/08/28/the-engineers-captivating-pharma-make-cells-not-software/ The Engineers Captivating Pharma Make Cells Not SoftwareThe ambitions of startups in the cell therapy space illustrates just how incredibly audacious – and routinely audacious -- biological engineering has become.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5d65cf5ae941d3008579db71Thu, 29 Aug 2019 00:00:00 +00002019-08-29T00:00:00ZThe ambitions of startups in the cell therapy space illustrates just how incredibly audacious – and routinely audacious -- biological engineering has become.https://www.forbes.com/sites/davidshaywitz/2019/08/23/ai-and-healthcare-is-the-bloom-finally-off-the-rose/ AI And Healthcare: Is The Bloom Finally Off The Rose?Following the predictable recent cycle of extravagant expectations -- and attendant disappointments -- around early efforts to apply AI to healthcare and drug discovery, we need to move from theoretic benefit and evangelical sales to established use cases and robust, clinically-relevant data.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5d608a4e1f2f4e0085852338Sat, 24 Aug 2019 01:16:00 +00002019-08-24T01:16:00ZFollowing the predictable recent cycle of extravagant expectations -- and attendant disappointments -- around early efforts to apply AI to healthcare and drug discovery, we need to move from theoretic benefit and evangelical sales to established use cases and robust, clinically-relevant data.https://www.forbes.com/sites/davidshaywitz/2019/08/16/in-praise-of-breadth-why-range-may-be-the-years-most-important-business-and-parenting-book/ In Praise of Breadth: Why "Range" May Be The Year's Most Important Business-And Parenting-BookRange author David Epstein worries our obsession with hyperspecialization has gotten out of hand, in the process obscuring an important counter-narrative that values breadth and lateral thinking, tolerates ambiguity and inefficiency, embraces meandering career paths and extols personal exploration.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5d5713cf8133ed00822526bcFri, 16 Aug 2019 21:19:00 +00002019-08-16T21:19:00ZRange author David Epstein worries our obsession with hyperspecialization has gotten out of hand, in the process obscuring an important counter-narrative that values breadth and lateral thinking, tolerates ambiguity and inefficiency, embraces meandering career paths and extols personal exploration.https://www.forbes.com/sites/davidshaywitz/2019/06/19/two-lessons-from-two-shoe-guys-what-allbirds-can-teach-health-tech-entrepreneurs/ Two Lessons From Two Shoe Guys: What Allbirds Can Teach Health Tech EntrepreneursTwo key lessons for health tech entrepreneurs from Allbirds founders: 1. understand what customers actually wants (virtue in itself may not be as compelling as you think); 2. incumbents may talk change but tend to embrace incremental improvements (so focus on that, rather than tech wonder).David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5d0a8bc1c1f8e700833ee2dfWed, 19 Jun 2019 19:52:00 +00002019-06-19T19:52:00ZTwo key lessons for health tech entrepreneurs from Allbirds founders: 1. understand what customers actually wants (virtue in itself may not be as compelling as you think); 2. incumbents may talk change but tend to embrace incremental improvements (so focus on that, rather than tech wonder).https://www.forbes.com/sites/davidshaywitz/2019/05/31/the-sociology-behind-data-silos-in-pharma-rd/ The Sociology Behind Data Silos In Pharma R&DFrom the perspective of those responsible for delivering the primary data analysis – the original reason the data were collected – there is generally no perceptible upside for investing precious and limited time and capital (and quite perceptible downsides) in high-falutin data initiatives.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5cf18c1d8a70c000839ed397Fri, 31 May 2019 20:44:00 +00002019-05-31T20:44:00ZFrom the perspective of those responsible for delivering the primary data analysis – the original reason the data were collected – there is generally no perceptible upside for investing precious and limited time and capital (and quite perceptible downsides) in high-falutin data initiatives.https://www.forbes.com/sites/davidshaywitz/2019/05/23/pharmas-desperate-struggle-to-teach-old-data-new-tricks/ Pharma's Desperate Struggle To Teach Old Data New TricksIn pharma R&D organizations and in hospital systems, any effort to glean novel insight from existing data represents a maddeningly difficult challenge.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5ce60c4ec8558b0084d32fcdThu, 23 May 2019 04:08:00 +00002019-05-23T04:08:00ZIn pharma R&D organizations and in hospital systems, any effort to glean novel insight from existing data represents a maddeningly difficult challenge.https://www.forbes.com/sites/davidshaywitz/2019/05/19/how-big-pharmas-simultaneously-repel-and-embrace-innovation/ How Big Pharmas Simultaneously Repel And Embrace InnovationSo often, the experience of innovation at large pharmas can be disappointing and stifling, but occasionally, under the right circumstances, it is transformative and elating.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5ce1f8883628e700835a4694Mon, 20 May 2019 01:09:00 +00002019-05-20T01:09:00ZSo often, the experience of innovation at large pharmas can be disappointing and stifling, but occasionally, under the right circumstances, it is transformative and elating.https://www.forbes.com/sites/davidshaywitz/2019/05/18/why-health-tech-entrepreneurs-should-visit-michaels/ Three Design Principles Health Tech Entrepreneurs Could Learn From Picture Framing At MichaelsArt supply store Michaels offers an elegant, technology-enabled approach to picture framing that offers three lessons for health tech entrepreneurs.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5ce0a78e3628e700835a43e0Sun, 19 May 2019 00:57:00 +00002019-05-19T00:57:00ZArt supply store Michaels offers an elegant, technology-enabled approach to picture framing that offers three lessons for health tech entrepreneurs.https://www.forbes.com/sites/davidshaywitz/2019/05/18/digital-medicine-digital-health-plus-evidence-plus-humility/ Digital Medicine: Digital Health, Plus Evidence, Plus HumilityI see a new generation of researchers who grew up immersed in data+digital beginning to populate incumbent healthcare organizations+pharma companies, bringing with them a new set of expectations+capabilities. With time, effort, and a bit of luck, I suspect they will be the change we all wish to see.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5ce0a0d53628e700835a43d1Sun, 19 May 2019 00:38:00 +00002019-05-19T00:38:00ZI see a new generation of researchers who grew up immersed in data+digital beginning to populate incumbent healthcare organizations+pharma companies, bringing with them a new set of expectations+capabilities. With time, effort, and a bit of luck, I suspect they will be the change we all wish to see.https://www.forbes.com/sites/davidshaywitz/2019/04/04/cancer-research-meeting-offers-cambrian-explosion-of-biology-opportunity-for-data-science/ Cancer Research Meeting Offers Cambrian Explosion of Biology, Opportunity For Data ScienceThis is a profoundly exciting and dynamic time in cancer research, as recent biological advances have revealed a range of therapeutic avenues and generated a palpable sense of hope and possibility. I am also encouraged by efforts utilizing data and tech as tools to solve specific research problems.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5ca6c5e4da7dcd00813232acFri, 5 Apr 2019 03:52:00 +00002019-04-05T03:52:00ZThis is a profoundly exciting and dynamic time in cancer research, as recent biological advances have revealed a range of therapeutic avenues and generated a palpable sense of hope and possibility. I am also encouraged by efforts utilizing data and tech as tools to solve specific research problems.https://www.forbes.com/sites/davidshaywitz/2019/03/18/enough-with-culture-focus-on-structure-biotech-entrepreneur-argues/ Enough With Culture -- Focus On Structure, Biotech Entrepreneur ArguesPharma desperately needs innovation; the question Safi Bahcall’s new book begs is whether senior pharma executives can structure their organizations in a fashion can liberate the creativity, and tolerate the uncertainty, innovation requires.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5c8fab1c64aaf9243c76663fMon, 18 Mar 2019 23:07:00 +00002019-03-18T23:07:00ZPharma desperately needs innovation; the question Safi Bahcall’s new book begs is whether senior pharma executives can structure their organizations in a fashion can liberate the creativity, and tolerate the uncertainty, innovation requires.https://www.forbes.com/sites/davidshaywitz/2019/03/07/amy-abernethy-for-fda-commissioner/ Amy Abernethy For FDA CommissionerIf appointed by President Trump to lead the FDA, Dr. Amy Abernethy would be a credit to the Administration, the Agency, and – mostly importantly – to the patients who would benefit from her vision, compassion, determination, and insight.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5c81e6f964aaf92a9c7a104dFri, 8 Mar 2019 04:18:00 +00002019-03-08T04:18:00ZIf appointed by President Trump to lead the FDA, Dr. Amy Abernethy would be a credit to the Administration, the Agency, and – mostly importantly – to the patients who would benefit from her vision, compassion, determination, and insight.https://www.forbes.com/sites/davidshaywitz/2019/02/04/what-is-a-data-science-mindset-and-does-pharma-rd-really-need-one/ What Is A Data Science Mindset -- And Does Pharma R&D Really Need One?Data scientists are optimistic about the opportunity to improve how new medicines are discovered; most traditional medical scientists (including most pharma researchers) are skeptical these new approaches will deliver benefit to patients, but convincible, saying, appropriately: “show me the data.”David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5c58c82864aaf93f2fe44009Mon, 4 Feb 2019 23:54:00 +00002019-02-04T23:54:00ZData scientists are optimistic about the opportunity to improve how new medicines are discovered; most traditional medical scientists (including most pharma researchers) are skeptical these new approaches will deliver benefit to patients, but convincible, saying, appropriately: “show me the data.”https://www.forbes.com/sites/davidshaywitz/2019/01/31/hard-lessons-for-would-be-healthcare-innovators-from-ucsf-expert/ Hard Lessons For Would-Be Healthcare Innovators From UCSF ExpertTech entrepreneurs should work closely with front-line innovators to ensure their company is focused on a relevant problem and developing an implementable solution; innovators must also recognize that robust evidence of impact (not just clicks) is essential for adoption by most established players.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5c53144564aaf93f2fe42fcaThu, 31 Jan 2019 16:03:00 +00002019-01-31T16:03:00ZTech entrepreneurs should work closely with front-line innovators to ensure their company is focused on a relevant problem and developing an implementable solution; innovators must also recognize that robust evidence of impact (not just clicks) is essential for adoption by most established players.https://www.forbes.com/sites/davidshaywitz/2019/01/20/pro-vaccination-message-should-be-apolitical-as-nyt-argues-but-fails-to-demonstrate/ Pro-Vaccination Message Should Be Apolitical, As NYT Argues But Fails To DemonstrateVaccination is a critically important public health measure. Anti-vaccination disinformation needs to be countered in a non-political fashion, as the NYT Editorial Board argues but fails to demonstrate.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5c44b65964aaf9368b3951dcSun, 20 Jan 2019 18:15:00 +00002019-01-20T18:15:00ZVaccination is a critically important public health measure. Anti-vaccination disinformation needs to be countered in a non-political fashion, as the NYT Editorial Board argues but fails to demonstrate.https://www.forbes.com/sites/davidshaywitz/2019/01/16/novartis-ceo-who-wanted-to-bring-tech-into-pharma-now-explains-why-its-so-hard/ Novartis CEO Who Wanted To Bring Tech Into Pharma Now Explains Why It's So HardWe need to bring our best technology – biological and digital – and our most creative people together to work on this monumental challenge. One clear take-away from the Narasimhan interview: pharma is at the very earliest stages of figuring out how to do this.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5c3ea17064aaf93f10ef2528Wed, 16 Jan 2019 05:02:00 +00002019-01-16T05:02:00ZWe need to bring our best technology – biological and digital – and our most creative people together to work on this monumental challenge. One clear take-away from the Narasimhan interview: pharma is at the very earliest stages of figuring out how to do this.https://www.forbes.com/sites/davidshaywitz/2019/01/04/what-i-learned-losing-80-pounds-in-2018/ What I learned Losing 80 Pounds In 2018A dream would be to attain my goal weight and then develop the routine to maintain it, so I wouldn't need to worry about falling off the wagon every single day. I doubt this is realistic. More likely, successful long-term weight loss will require constant vigilance to maintain. One day at a time.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5c2fcce664aaf93f10eeff00Fri, 4 Jan 2019 22:05:00 +00002019-01-04T22:05:00ZA dream would be to attain my goal weight and then develop the routine to maintain it, so I wouldn't need to worry about falling off the wagon every single day. I doubt this is realistic. More likely, successful long-term weight loss will require constant vigilance to maintain. One day at a time.https://www.forbes.com/sites/davidshaywitz/2019/01/03/data-scientist-explains-how-ais-seductive-power-can-mislead-biomarker-researchers/ Data Scientist Explains How AI's Seductive Power Can Mislead Biomarker ResearchersTranslating AI approaches to contemporary challenges in clinical diagnosis is not just difficult, but really tricky; the most significant challenge may well be that the power of AI permits us to convince ourselves we’ve found something *significant*, because it’s relatively easy to find *something*.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5c2ea8b064aaf93f10eefb79Fri, 4 Jan 2019 00:48:00 +00002019-01-04T00:48:00ZTranslating AI approaches to contemporary challenges in clinical diagnosis is not just difficult, but really tricky; the most significant challenge may well be that the power of AI permits us to convince ourselves we’ve found something *significant*, because it’s relatively easy to find *something*.https://www.forbes.com/sites/davidshaywitz/2018/12/24/aural-pleasures-2018-edition/ Aural Pleasures -- 2018 EditionMy current favorite podcasts -- and audiobooks -- for healthcare innovators.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5c21aae764aaf93f10eee203Tue, 25 Dec 2018 04:26:00 +00002018-12-25T04:26:00ZMy current favorite podcasts -- and audiobooks -- for healthcare innovators.https://www.forbes.com/sites/davidshaywitz/2018/12/24/we-are-not-a-dashboard-contesting-the-tyranny-of-metrics-measurement-and-managerialism/ We Are Not A Dashboard: Contesting The Tyranny Of Metrics, Measurement, And ManagerialismData sciences and technology could, and must, play a vital role. But they haven’t earned the right to be considered an end in themselves. They represent potentially valuable tools, ideally in the hands of experienced, inquisitive practitioners, who uniquely appreciate the subtleties of their domain.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5c21505664aaf93f10eee1c1Mon, 24 Dec 2018 22:13:00 +00002018-12-24T22:13:00ZData sciences and technology could, and must, play a vital role. But they haven’t earned the right to be considered an end in themselves. They represent potentially valuable tools, ideally in the hands of experienced, inquisitive practitioners, who uniquely appreciate the subtleties of their domain.https://www.forbes.com/sites/davidshaywitz/2018/12/18/shuttered-magazine-editor-struggles-with-collaboration-lesson-health-data-advocates-sadly-learned/ Shuttered Magazine Editor Struggles With Collaboration Lesson Health Data Advocates Sadly LearnedA conservative editor is mugged by reality; health data advocates would have been far less surprised.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5c190e8864aaf93f10eecc98Tue, 18 Dec 2018 15:37:00 +00002018-12-18T15:37:00ZA conservative editor is mugged by reality; health data advocates would have been far less surprised.https://www.forbes.com/sites/davidshaywitz/2018/12/17/amy-abernethy-poised-to-propel-fda-into-tech-savvy-patient-centric-future/ Amy Abernethy: Poised To Propel FDA Into Tech-Savvy, Patient-Centric FutureAs our focus expands from approvals to outcomes, fluency with real-world data, and the tools to generate and analyze this information, will be ever-more critical. Amy Abernethy has the right experience, attributes, and instincts to catalyze the FDA’s embrace of this imminent patient-centric future.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5c1822c164aaf93f10eeca15Mon, 17 Dec 2018 22:51:00 +00002018-12-17T22:51:00ZAs our focus expands from approvals to outcomes, fluency with real-world data, and the tools to generate and analyze this information, will be ever-more critical. Amy Abernethy has the right experience, attributes, and instincts to catalyze the FDA’s embrace of this imminent patient-centric future.https://www.forbes.com/sites/davidshaywitz/2018/11/09/ai-doesnt-ask-why-but-physicians-and-drug-developers-want-to-know/ AI Doesn't Ask Why -- But Physicians And Drug Developers Want To KnowAI relates often imperceptible observations to outcome in a fashion that’s unapologetically oblivious to mechanism, which challenges physicians and drug developers by explicitly severing utility from foundational scientific understanding.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5be5cc9964aaf961d756dd1cFri, 9 Nov 2018 18:46:00 +00002018-11-09T18:46:00ZAI relates often imperceptible observations to outcome in a fashion that’s unapologetically oblivious to mechanism, which challenges physicians and drug developers by explicitly severing utility from foundational scientific understanding.https://www.forbes.com/sites/davidshaywitz/2018/10/01/californias-new-diversity-law-aims-to-help-businesses-help-themselves/ California's New Diversity Law Aims To Help Businesses Help ThemselvesThe reason diversity works -- the "speedbump effect" -- may also relate to why it's challenging for some businesses to adopt, as the efficiencies of homogeneity can be alluring. New legislation in California aims to nudge companies towards greater gender diversity on corporate boards.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5bb2c70564aaf93e2ca3db21Tue, 2 Oct 2018 01:58:00 +00002018-10-02T01:58:00ZThe reason diversity works -- the "speedbump effect" -- may also relate to why it's challenging for some businesses to adopt, as the efficiencies of homogeneity can be alluring. New legislation in California aims to nudge companies towards greater gender diversity on corporate boards.https://www.forbes.com/sites/davidshaywitz/2018/08/09/from-durham-the-future-of-clinical-research-looks-a-lot-like-implementation-science/ From Durham, The Future Of Clinical Research Looks A Lot Like Implementation ScienceLeading clinical researchers --such as the leaders at Duke -- are increasingly focused on implementation science: closing the gap between theory and practice, between the promise of a “successful” clinical trial and the actual outcomes of real world patients afflicted with the associated condition.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5b6c52e264aaf942a5e2e8f6Thu, 9 Aug 2018 15:20:00 +00002018-08-09T15:20:00ZLeading clinical researchers --such as the leaders at Duke -- are increasingly focused on implementation science: closing the gap between theory and practice, between the promise of a “successful” clinical trial and the actual outcomes of real world patients afflicted with the associated condition.https://www.forbes.com/sites/davidshaywitz/2018/06/04/learning-the-right-lesson-from-theranos-fraud-is-bad-wanting-to-disrupt-healthcare-isnt/ Learning The Right Lesson From Theranos: Fraud Is Bad, Wanting To Disrupt Healthcare Isn'tOur challenge is figuring out how to reject Theranos as fraudulent and immoral without rejecting much of what Theranos both embraced and falsely wrapped itself in – an ethos that change is possible, technology can empower us, and incumbents should be challenged.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5b15ac8c64aaf96fd24bc98eMon, 4 Jun 2018 21:31:00 +00002018-06-04T21:31:00ZOur challenge is figuring out how to reject Theranos as fraudulent and immoral without rejecting much of what Theranos both embraced and falsely wrapped itself in – an ethos that change is possible, technology can empower us, and incumbents should be challenged.https://www.forbes.com/sites/davidshaywitz/2018/05/22/should-tech-entrepreneurs-aspire-to-fix-clinical-trials-or-reinvent-them/ Should Tech Entrepreneurs Aspire To Fix Clinical Trials Or Reinvent Them?The cost and time of clinical trials are a huge hurdle to the development of new treatments. Should tech entrepreneurs focus on making existing clinical trial processes more efficient, or seek to reinvent clinical trials by figuring out new ways to use data that are already captured?David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5b02163d64aaf968807915eeTue, 22 May 2018 21:56:00 +00002018-05-22T21:56:00ZThe cost and time of clinical trials are a huge hurdle to the development of new treatments. Should tech entrepreneurs focus on making existing clinical trial processes more efficient, or seek to reinvent clinical trials by figuring out new ways to use data that are already captured?https://www.forbes.com/sites/davidshaywitz/2018/05/11/will-real-world-performance-replace-rcts-as-healthcares-most-important-standard/ Will Real World Performance Replace RCTs As Healthcare's Most Important Standard?The ability to measure the performance of an intervention in trusted, near-real-time fashion will profoundly disrupt both pharma and healthcare.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5af513fc64aaf91021c309cbFri, 11 May 2018 04:25:00 +00002018-05-11T04:25:00ZThe ability to measure the performance of an intervention in trusted, near-real-time fashion will profoundly disrupt both pharma and healthcare.innovation-rxhttps://www.forbes.com/sites/davidshaywitz/2018/04/01/the-lab-tests-behind-immuno-oncology-precise-enough/ The Lab Tests Behind Immuno-Oncology: Precise Enough?Researchers will need to integrate knowledge of genetic, cellular, tissue, and even microbiome factors to better understand the biology of cancer, to predict patient response more accurately, and to guide the development of new treatments for the many patients poorly served by existing approaches.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5ac15b1e64aaf9704accb02bSun, 1 Apr 2018 23:00:00 +00002018-04-01T23:00:00ZResearchers will need to integrate knowledge of genetic, cellular, tissue, and even microbiome factors to better understand the biology of cancer, to predict patient response more accurately, and to guide the development of new treatments for the many patients poorly served by existing approaches.https://www.forbes.com/sites/davidshaywitz/2018/03/09/beyond-flatiron-the-rising-power-of-oncology-clinical-data-companies/ Beyond Flatiron: The Rising Power Of Oncology Clinical Data CompaniesIt will behoove drug makers to anticipate real world efficacy prior to launch, as the limiting factor for commercialization could soon be not whether a drug is approved by the FDA, based on clinical trial data, but whether it’s validated by clinical data companies, based on real-world performance.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5aa1388764aaf9689c48e1e5Fri, 9 Mar 2018 06:04:00 +00002018-03-09T06:04:00ZIt will behoove drug makers to anticipate real world efficacy prior to launch, as the limiting factor for commercialization could soon be not whether a drug is approved by the FDA, based on clinical trial data, but whether it’s validated by clinical data companies, based on real-world performance.https://www.forbes.com/sites/davidshaywitz/2018/02/20/biotech-ceo-gini-deshpande-investors-need-evolved-view-of-successful-leader-phenotype/ Biotech CEO Gini Deshpande: Investors Need Evolved View Of Successful Leader Phenotype"Women leaders tend not to be ‘in your face,’ aggressive, and assertive in that manner. I think there’s a quiet strength that some women can bring to the table." - NuMedii CEO and founder Gini DeshpandeDavid Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5a8c3ab664aaf9689c48a5b4Tue, 20 Feb 2018 15:27:00 +00002018-02-20T15:27:00Z"Women leaders tend not to be ‘in your face,’ aggressive, and assertive in that manner. I think there’s a quiet strength that some women can bring to the table." - NuMedii CEO and founder Gini Deshpandehttps://www.forbes.com/sites/davidshaywitz/2018/02/18/the-deeply-human-core-of-roches-2-1b-tech-acquisition-and-why-they-did-it/ The Deeply Human Core Of Roche's $2.1 Billion Tech Acquisition -- And Why It Made ItFlatiron’s key insight was that, in cancer, at least half of the most important data in health records isn’t in structured data fields but rather in unstructured data, the free text fields of pathology reports and clinical notes, and extracting this information (at least today) requires people.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5a8892f064aaf9689c48a0d3Sun, 18 Feb 2018 16:32:00 +00002018-02-18T16:32:00ZFlatiron’s key insight was that, in cancer, at least half of the most important data in health records isn’t in structured data fields but rather in unstructured data, the free text fields of pathology reports and clinical notes, and extracting this information (at least today) requires people.https://www.forbes.com/sites/davidshaywitz/2018/01/22/is-pharmas-data-problem-technical-or-cultural/ Is Pharma's Data Problem Technical Or Cultural?At many biopharmas today, drug development teams toil pretty much as they always have, while data groups collect and assemble both data and talent, in relative isolation. It is a tale of two cultures worthy of C.P. Snow.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5a657d7264aaf9695a78da49Mon, 22 Jan 2018 06:26:00 +00002018-01-22T06:26:00ZAt many biopharmas today, drug development teams toil pretty much as they always have, while data groups collect and assemble both data and talent, in relative isolation. It is a tale of two cultures worthy of C.P. Snow.https://www.forbes.com/sites/davidshaywitz/2018/01/13/at-j-p-morgan-a-sense-that-the-long-promised-biotech-future-has-arrived-is-tech-disruption-next/ At J.P. Morgan, A Sense That The Long-Promised Biotech Future Has Arrived; Is Tech Disruption Next?There's been remarkable progress in the tools available for collecting and analyzing data. These tools are too powerful and too important not to impact how we think about biology and drug discovery. The question is how to bring these tools to bear in developing impactful new medicines for patients.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5a599d8a64aaf971982fbd48Sat, 13 Jan 2018 06:38:00 +00002018-01-13T06:38:00ZThere's been remarkable progress in the tools available for collecting and analyzing data. These tools are too powerful and too important not to impact how we think about biology and drug discovery. The question is how to bring these tools to bear in developing impactful new medicines for patients.pharma-healthcarehttps://www.forbes.com/sites/davidshaywitz/2017/12/17/aural-pleasures-2017-edition-podcasts-for-health-entrepreneurs/ Aural Pleasures, 2017 Edition: Podcasts For Health EntrepreneursTop 2017 podcasts for healthcare entrepreneurs.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5a36fe4664aaf948a7b9cecdMon, 18 Dec 2017 01:20:00 +00002017-12-18T01:20:00ZTop 2017 podcasts for healthcare entrepreneurs.https://www.forbes.com/sites/davidshaywitz/2017/12/10/winning-health-tech-entrepreneurs-will-focus-on-implementation-not-fetishize-invention/ Winning Health Tech Entrepreneurs Will Focus On Implementation, Not Fetishize InventionPowerful emerging technologies afford the opportunity to radically reconceptualize our world, and profoundly refine our understanding of health and disease. But our greatest challenge may be the long, complex path towards implementation that we should have anticipated, and with we must now contend.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5a2dc55e64aaf948a7b9bb4dMon, 11 Dec 2017 01:36:00 +00002017-12-11T01:36:00ZPowerful emerging technologies afford the opportunity to radically reconceptualize our world, and profoundly refine our understanding of health and disease. But our greatest challenge may be the long, complex path towards implementation that we should have anticipated, and with we must now contend.pharma-healthcarehttps://www.forbes.com/sites/davidshaywitz/2017/10/24/why-healthcare-entrepreneurs-developing-devices-or-software-better-grok-sales-marketing/ Why Healthcare Entrepreneurs Developing Devices Or Software Better Grok Sales & MarketingWhile life science entrepreneurs need to surmount the complexities of human biology, device and software entrepreneurs need a sales team to move what you’ve made today, a marketing team to figure out what you should make tomorrow, and engineering team to figure out what you can make tomorrow.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/59efb62464aaf9293e08fc2aTue, 24 Oct 2017 22:05:00 +00002017-10-24T22:05:00ZWhile life science entrepreneurs need to surmount the complexities of human biology, device and software entrepreneurs need a sales team to move what you’ve made today, a marketing team to figure out what you should make tomorrow, and engineering team to figure out what you can make tomorrow.https://www.forbes.com/sites/davidshaywitz/2017/10/24/why-precision-research-may-lead-to-blockbuster-not-customized-medicines/ Why Precision Research May Lead To Blockbuster, Not Customized, MedicinesPrecision medicine may not produce customized cures for each patient, but instead offer the hope that in elucidating the complex genetic architecture of disease, we will be able to identify and develop novel therapeutics each offering benefit to large numbers of suffering patients.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/59ef468664aaf922be63d121Tue, 24 Oct 2017 18:47:00 +00002017-10-24T18:47:00ZPrecision medicine may not produce customized cures for each patient, but instead offer the hope that in elucidating the complex genetic architecture of disease, we will be able to identify and develop novel therapeutics each offering benefit to large numbers of suffering patients.https://www.forbes.com/sites/davidshaywitz/2017/07/26/the-startling-history-behind-mercks-new-cancer-blockbuster/ The Startling History Behind Merck's New Cancer BlockbusterThe success of Merck’s blockbuster cancer drug pembrolizumab (Keytruda) was anything but inevitable. It was discovered accidentally, weathered two company acquisitions, and nearly out-licensed for next to nothing -- before it was developed in one of the most aggressive pharma programs in history.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/597821b664aaf93605d177e2Wed, 26 Jul 2017 06:15:00 +00002017-07-26T06:15:00ZThe success of Merck’s blockbuster cancer drug pembrolizumab (Keytruda) was anything but inevitable. It was discovered accidentally, weathered two company acquisitions, and nearly out-licensed for next to nothing -- before it was developed in one of the most aggressive pharma programs in history.https://www.forbes.com/sites/davidshaywitz/2017/07/02/the-best-positioned-tech-giant-in-healthcare-the-answer-might-surprise-you/ The Best-Positioned Tech Giant In Healthcare? The Answer Might Surprise YouThe tech giant you hear about the least in the context of healthcare – Facebook – may actually be the company influencing healthcare the most, and may also be the best positioned to support the patient-centered future that so many imagine.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5959616564aaf930c1a2bb5fSun, 2 Jul 2017 21:32:00 +00002017-07-02T21:32:00ZThe tech giant you hear about the least in the context of healthcare – Facebook – may actually be the company influencing healthcare the most, and may also be the best positioned to support the patient-centered future that so many imagine.https://www.forbes.com/sites/davidshaywitz/2017/06/27/beware-of-tidy-success-narratives-in-pharma-and-in-life/ Beware Of Tidy Success Narratives -- In Pharma, And In Life“If your idea succeeds, everybody says you’re persistent,” pioneering Harvard surgeon Folkman said. “If it doesn’t, you’re obstinate.”David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5951dadb64aaf941135b5415Tue, 27 Jun 2017 04:35:00 +00002017-06-27T04:35:00Z“If your idea succeeds, everybody says you’re persistent,” pioneering Harvard surgeon Folkman said. “If it doesn’t, you’re obstinate.”https://www.forbes.com/sites/davidshaywitz/2017/06/25/how-med-centers-and-pharmas-respond-to-technological-innovation-the-four-r/ How Medical Centers And Pharmas Respond To Technological Innovation: The Four RsMedical centers and pharma companies tend to approach new innovation -- and especially new technologies -- in one of four ways: Resist, Refit, Reduce, and Renew.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/594f476864aaf941135b4bddSun, 25 Jun 2017 05:49:00 +00002017-06-25T05:49:00ZMedical centers and pharma companies tend to approach new innovation -- and especially new technologies -- in one of four ways: Resist, Refit, Reduce, and Renew.https://www.forbes.com/sites/davidshaywitz/2017/05/17/googles-verily-business-or-salon/ Google's Verily: Business Or Salon?With lots of funding, a seemingly endless supply of medical and technology talent, and a global supply of eager partners hoping for a brush with Google greatness, Verily is emerging as a crucible for health and data thinking. But is it also a business?David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/591cbbac64aaf941135aa523Wed, 17 May 2017 21:37:00 +00002017-05-17T21:37:00ZWith lots of funding, a seemingly endless supply of medical and technology talent, and a global supply of eager partners hoping for a brush with Google greatness, Verily is emerging as a crucible for health and data thinking. But is it also a business?https://www.forbes.com/sites/davidshaywitz/2017/05/16/why-ai-and-healthcare-must-get-past-their-tired-tribalism-and-learn-to-make-nice/ Why AI And Healthcare Must Learn To Play TogetherSome technologists and data scientists believe, ardently, that the future is already here – that we already have ability to use AI to solve important problems in healthcare, and that it’s intransigent docs who are standing in the way.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/591a7f3b64aaf941135a9b65Tue, 16 May 2017 05:05:00 +00002017-05-16T05:05:00ZSome technologists and data scientists believe, ardently, that the future is already here – that we already have ability to use AI to solve important problems in healthcare, and that it’s intransigent docs who are standing in the way.https://www.forbes.com/sites/davidshaywitz/2017/05/12/no-lie-engaging-new-book-brings-behavioral-science-into-the-era-of-big-data/ No Lie: Engaging New Book Brings Behavioral Science Into The Era of Big DataIn his engaging, enjoyable, and easily accessible new book, Everybody Lies, data scientist and New York Times columnist Seth Stephens-Davidowitz brings behavioral economics into the era of big data.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/59161fd164aaf941135a9130Fri, 12 May 2017 21:11:00 +00002017-05-12T21:11:00ZIn his engaging, enjoyable, and easily accessible new book, Everybody Lies, data scientist and New York Times columnist Seth Stephens-Davidowitz brings behavioral economics into the era of big data.https://www.forbes.com/sites/davidshaywitz/2017/04/25/three-key-investment-challenges-at-the-interface-of-health-and-technology/ Three Key Investment Challenges At The Intersection Of Health And TechnologySuccess stories of startups at the interface of technology and health are emerging, but to be a part of them, traditional tech investors may need to get out of their comfort zone a bit, and learn to love, or at least embrace, services, messiness, and regulation.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/58feb13364aaf90433d9acb0Tue, 25 Apr 2017 04:03:00 +00002017-04-25T04:03:00ZSuccess stories of startups at the interface of technology and health are emerging, but to be a part of them, traditional tech investors may need to get out of their comfort zone a bit, and learn to love, or at least embrace, services, messiness, and regulation.https://www.forbes.com/sites/davidshaywitz/2017/04/19/what-googley-medical-data-scientists-hope-to-learn-by-studying-10000-volunteers/ What Alphabet Medical Data Scientists Hope To Learn By Studying 10,000 VolunteersGoogle has described its mission as organizing the world’s information. Today, Verily, the medical arm of Alphabet, Google’s parent company, announced the launch of an ambitious initiative that seeks to collect and analyze extensive data from 10,000 volunteers, in a clinical study called “Baseline.”David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/58f6aabb64aaf90433d994a8Wed, 19 Apr 2017 12:00:00 +00002017-04-19T12:00:00ZGoogle has described its mission as organizing the world’s information. Today, Verily, the medical arm of Alphabet, Google’s parent company, announced the launch of an ambitious initiative that seeks to collect and analyze extensive data from 10,000 volunteers, in a clinical study called “Baseline.”https://www.forbes.com/sites/davidshaywitz/2017/04/14/why-alphabets-new-wearable-is-significant-and-what-they-left-out/ Why Alphabet's New Wearable Is Significant -- And What They Left OutVerily's new wearable speaks to the company's seriousness of purpose, as well as to the importance of collecting complex, real-world data in a robust and reliable fashion. Their next goal should be involving users as participants, not subjects.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/58f15d7164aaf90433d98686Fri, 14 Apr 2017 23:57:00 +00002017-04-14T23:57:00ZVerily's new wearable speaks to the company's seriousness of purpose, as well as to the importance of collecting complex, real-world data in a robust and reliable fashion. Their next goal should be involving users as participants, not subjects.https://www.forbes.com/sites/davidshaywitz/2017/04/13/why-tech-companies-hire-chief-medical-officers/ Why Tech Companies Hire Chief Medical OfficersAs more companies approach the intersection of technology and health, many have adopted pharma's Chief Medical Officer model, looking for an authoritative voice to represent healthcare inside the company, as well a credible voice to represent the company to the external healthcare community.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/58eedef964aaf90433d97e5bThu, 13 Apr 2017 04:22:00 +00002017-04-13T04:22:00ZAs more companies approach the intersection of technology and health, many have adopted pharma's Chief Medical Officer model, looking for an authoritative voice to represent healthcare inside the company, as well a credible voice to represent the company to the external healthcare community.https://www.forbes.com/sites/davidshaywitz/2017/03/28/commercializing-science-integral-to-translation-not-a-dirty-word/ To Translate Medical Science Effectively, Researchers Must Understand CommercializationWe need to get past the patronizing and paternalistic concern that teaching physicians and researchers how scientific knowledge gets implemented and, yes, commercialized will somehow offend their delicate sensibilities, corrupt their moral integrity, and seduce them to “the dark side.”David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/58d9a1b064aaf936cc6d54f0Tue, 28 Mar 2017 08:50:00 +00002017-03-28T08:50:00ZWe need to get past the patronizing and paternalistic concern that teaching physicians and researchers how scientific knowledge gets implemented and, yes, commercialized will somehow offend their delicate sensibilities, corrupt their moral integrity, and seduce them to “the dark side.”https://www.forbes.com/sites/davidshaywitz/2017/03/08/can-silicon-valley-cure-diabetes-with-low-carbs-and-high-tech/ Can Silicon Valley Cure Diabetes With Low Carbs And High Tech?Imagine a treatment for Type 2 diabetes that requires neither surgery, medication nor calorie restriction, but rather relies on adherence to a low-carb, high-fat diet, tracked by regular finger-stick checks of blood chemistry, and guided remotely by a team of physicians, coaches, and algorithms?David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/58bf790e64aaf910436db955Wed, 8 Mar 2017 08:00:00 +00002017-03-08T08:00:00ZImagine a treatment for Type 2 diabetes that requires neither surgery, medication nor calorie restriction, but rather relies on adherence to a low-carb, high-fat diet, tracked by regular finger-stick checks of blood chemistry, and guided remotely by a team of physicians, coaches, and algorithms?https://www.forbes.com/sites/davidshaywitz/2017/03/03/genetics-as-placebo/ Precision Credulity: How Specious Genetic Tests Might Motivate Real Behavior ChangeIt would be ironic, certainly, if the primary benefit of many genetic tests proves to be behavioral, but what’s the harm, especially if it’s paid for by consumers? The unacceptable cost of eroding trust in the underlying science.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/58b9a64b64aaf95dd3d689d4Fri, 3 Mar 2017 17:43:00 +00002017-03-03T17:43:00ZIt would be ironic, certainly, if the primary benefit of many genetic tests proves to be behavioral, but what’s the harm, especially if it’s paid for by consumers? The unacceptable cost of eroding trust in the underlying science.https://www.forbes.com/sites/davidshaywitz/2017/02/06/trump-wants-to-return-power-to-patients-consumer-ordered-lab-tests-may-be-perfect-place-to-start/ Trump Wants To Return Power To Patients, And Consumer-Ordered Lab Tests May Be Perfect Place To StartTo the extent that the Trump administration seeks an opportunity to radically redefine healthcare, place more power in the hands of patients, and nurture a consumer-focused health ecosystem, they could do a lot worse than learning from the example of Arizona and other states where DAT is the law.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5897fe2464aaf925566b588fMon, 6 Feb 2017 11:00:00 +00002017-02-06T11:00:00ZTo the extent that the Trump administration seeks an opportunity to radically redefine healthcare, place more power in the hands of patients, and nurture a consumer-focused health ecosystem, they could do a lot worse than learning from the example of Arizona and other states where DAT is the law.https://www.forbes.com/sites/davidshaywitz/2017/01/21/evidation-health-ceo-shares-her-own-hidden-figures-experience/ Evidation Health CEO Shares Her Own 'Hidden Figures' ExperienceWhile 1989 hardly seems like the distant past, the (few) female engineers in the aerospace sector at the time were encouraged to adhere to a dress code that basically translated to skirts, pantyhose, and heels.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5883ee1464aaf925566b0f10Sat, 21 Jan 2017 23:52:00 +00002017-01-21T23:52:00ZWhile 1989 hardly seems like the distant past, the (few) female engineers in the aerospace sector at the time were encouraged to adhere to a dress code that basically translated to skirts, pantyhose, and heels.https://www.forbes.com/sites/davidshaywitz/2016/12/20/when-science-finally-confirms-your-cherished-beliefs-worry/ When Science Finally Confirms Your Cherished Beliefs -- WorryTo practice science is to appreciate the extent to which science occurs in a social context, and to recognize all findings are not created equal. Results that support conclusions the community wants to believe face a lower bar to publication than work that threatens to endorse unpopular beliefs.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/58599a3864aaf96e0fc743f6Tue, 20 Dec 2016 21:09:00 +00002016-12-20T21:09:00ZTo practice science is to appreciate the extent to which science occurs in a social context, and to recognize all findings are not created equal. Results that support conclusions the community wants to believe face a lower bar to publication than work that threatens to endorse unpopular beliefs.https://www.forbes.com/sites/davidshaywitz/2016/12/17/aural-pleasure-my-favorite-podcasts-of-2016/ Aural Pleasure: My Favorite Podcasts Of 2016Healthcare entrepreneurs and others who have discovered podcasts can accesses what at times feels like an embarrassment of riches – a diverse and rapidly-growing collection of excellent, enjoyable programs. Here are my favorites.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5854c56964aaf96e0fc73472Sat, 17 Dec 2016 05:14:00 +00002016-12-17T05:14:00ZHealthcare entrepreneurs and others who have discovered podcasts can accesses what at times feels like an embarrassment of riches – a diverse and rapidly-growing collection of excellent, enjoyable programs. Here are my favorites.https://www.forbes.com/sites/davidshaywitz/2016/12/15/ten-savvy-posts-healthcare-entrepreneurs-may-have-missed-in-2016/ Ten Favorite Healthcare Commentaries Of 2016In a year characterized by the extremes of rhetorical, healthcare entrepreneurs have been blessed with a number of thoughtful commentaries represent the opposite extreme. The selections cited here are measured, insightful, and pragmatic, embracing complexity, and acknowledging uncertainty.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5852153664aaf96e0fc7281aThu, 15 Dec 2016 05:01:00 +00002016-12-15T05:01:00ZIn a year characterized by the extremes of rhetorical, healthcare entrepreneurs have been blessed with a number of thoughtful commentaries represent the opposite extreme. The selections cited here are measured, insightful, and pragmatic, embracing complexity, and acknowledging uncertainty.https://www.forbes.com/sites/davidshaywitz/2016/12/12/two-must-read-science-books-and-why-youve-only-heard-of-one/ Two Must-Read Science Books -- And Why You've Only Heard Of OnePrecision medicine fans were treated this year to two must-read popular science books – one you’ve probably heard of, written by a Pulitzer Prize-winning physician-author, the other, less familiar, produced by a self-published biotech writer who grew up “shoveling pig sh-t” on a farm in Wisconsin.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/584e2c5164aaf96759a0bc3eMon, 12 Dec 2016 05:17:00 +00002016-12-12T05:17:00ZPrecision medicine fans were treated this year to two must-read popular science books – one you’ve probably heard of, written by a Pulitzer Prize-winning physician-author, the other, less familiar, produced by a self-published biotech writer who grew up “shoveling pig sh-t” on a farm in Wisconsin.https://www.forbes.com/sites/davidshaywitz/2016/12/09/health-tech-2016-a-year-to-recalibrate/ Health Tech 2016: A Year To RecalibrateAmong the key health technology lessons that 2016 has reinforced: biology is fiendishly complex; data ≠ insight; impacting health–whether making new drugs or meaningfully changing behavior – is hard; and palpable progress, experienced by patients, is starting to occur (and is tremendously exciting).David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/584a2bc064aaf96759a0b2ddFri, 9 Dec 2016 05:01:00 +00002016-12-09T05:01:00ZAmong the key health technology lessons that 2016 has reinforced: biology is fiendishly complex; data ≠ insight; impacting health–whether making new drugs or meaningfully changing behavior – is hard; and palpable progress, experienced by patients, is starting to occur (and is tremendously exciting).https://www.forbes.com/sites/davidshaywitz/2016/11/20/the-vital-role-for-nevertrump-scientists-like-harvards-jeff-flier-in-new-administration/ The Vital Role For #NeverTrump Scientists -- Like Harvard's Jeff Flier -- In The New AdministrationOur nation’s continued leadership in biomedical science is vitally important for our collective future. The new administration must seek to recruit the best talent – even NeverTrumpers; similarly those who are tagged – even NeverTrumpers --must consider serving, for the benefit of the country.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5831c85764aaf93de4c2d8e4Sun, 20 Nov 2016 16:16:00 +00002016-11-20T16:16:00ZOur nation’s continued leadership in biomedical science is vitally important for our collective future. The new administration must seek to recruit the best talent – even NeverTrumpers; similarly those who are tagged – even NeverTrumpers --must consider serving, for the benefit of the country.https://www.forbes.com/sites/davidshaywitz/2016/10/29/pop-star-d-a-wallach-champions-genetic-testing-at-d-c-conference-others-remain-wary/ Pop Star D.A. Wallach Champions Genetic Testing At D.C. Conference, But Others Remain WaryA genetic sequence may be described with great precision; the real-world implications of this information are rarely as precisely defined.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5815299d64aaf93de4c26a7aSat, 29 Oct 2016 23:13:00 +00002016-10-29T23:13:00ZA genetic sequence may be described with great precision; the real-world implications of this information are rarely as precisely defined.https://www.forbes.com/sites/davidshaywitz/2016/09/20/on-silicon-valley-immigration-and-american-greatness/ On Silicon Valley, Immigration And American GreatnessI wish more Americans had the opportunity to view immigration through this lens, and to viscerally appreciate the uncountable, extraordinary ways that new and recent arrivals contribute every day to American greatness.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/57e188a564aaf93de4c1a130Tue, 20 Sep 2016 19:29:00 +00002016-09-20T19:29:00ZI wish more Americans had the opportunity to view immigration through this lens, and to viscerally appreciate the uncountable, extraordinary ways that new and recent arrivals contribute every day to American greatness.https://www.forbes.com/sites/davidshaywitz/2016/09/20/activity-trackers-fail-but-thats-not-whats-most-surprising-about-new-research-paper/ Activity Trackers Fail -- But That's Not What's Most Surprising About New Research PaperThe real mystery of this paper isn’t why the addition of wearable trackers doesn’t produce weight loss; rather, it’s what to make of data demonstrating differences in weight loss despite comparable amounts of physical activity and dietary intake.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/57e16d2d64aaf93de4c1a034Tue, 20 Sep 2016 17:15:00 +00002016-09-20T17:15:00ZThe real mystery of this paper isn’t why the addition of wearable trackers doesn’t produce weight loss; rather, it’s what to make of data demonstrating differences in weight loss despite comparable amounts of physical activity and dietary intake.https://www.forbes.com/sites/davidshaywitz/2016/09/20/evolving-notions-of-the-right-stuff-in-space-flight-and-in-medicine/ Evolving Notions Of The Right Stuff -- In Spaceflight And In MedicineAn increasing number of doctors are moving from an individual, relationship-oriented model of care to a more transaction, team-based approach; are we losing something vital in the process?David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/57e0b44464aaf93de4c19cf9Tue, 20 Sep 2016 04:25:00 +00002016-09-20T04:25:00ZAn increasing number of doctors are moving from an individual, relationship-oriented model of care to a more transaction, team-based approach; are we losing something vital in the process?https://www.forbes.com/sites/davidshaywitz/2016/08/24/biotech-exec-miralles-describes-living-in-translation/ Biotech Exec Miralles Describes Living In TranslationWhat you appreciate every day in clinical medicine but may lose in the private sector is the “contact with suffering," according to Diego Miralles.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/57be585d64aaf97fcd6f8e41Thu, 25 Aug 2016 02:54:00 +00002016-08-25T02:54:00ZWhat you appreciate every day in clinical medicine but may lose in the private sector is the “contact with suffering," according to Diego Miralles.https://www.forbes.com/sites/davidshaywitz/2016/07/29/are-makers-rebranding-home-ec-or-reimagining-it/ Are Makers Rebranding Home Ec Or Reimagining It?As cheesy as “innovation mindset” sounds, it might actually represent just the right way introduce kids to useful life skills, framing the learning process in way that engages, challenges, and inspires participants while augmenting their agency.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/579beff064aaf95fe1539d97Sat, 30 Jul 2016 01:02:00 +00002016-07-30T01:02:00ZAs cheesy as “innovation mindset” sounds, it might actually represent just the right way introduce kids to useful life skills, framing the learning process in way that engages, challenges, and inspires participants while augmenting their agency.https://www.forbes.com/sites/davidshaywitz/2016/06/30/first-hand-account-the-biden-moonshot-summit/ Firsthand Account: The Biden Moonshot SummitGavin Belson captures challenge of data sharing in healthcare with his comment, "“I don't know about you people, but I don't want to live in a world where someone else makes the world a better place better than we do.”David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/57754fe264aaf9403d644c45Thu, 30 Jun 2016 17:20:00 +00002016-06-30T17:20:00ZGavin Belson captures challenge of data sharing in healthcare with his comment, "“I don't know about you people, but I don't want to live in a world where someone else makes the world a better place better than we do.”https://www.forbes.com/sites/davidshaywitz/2016/06/23/can-apple-teach-silicon-valley-to-think-different-about-health/ Can Apple Teach Silicon Valley To Think Different About Health?Silicon Valley is doing what it does best – learning from experience, iterating, adjusting, trying again. And it’s not just Apple.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/576c720964aaf91e7e9330ccThu, 23 Jun 2016 23:51:00 +00002016-06-23T23:51:00ZSilicon Valley is doing what it does best – learning from experience, iterating, adjusting, trying again. And it’s not just Apple.https://www.forbes.com/sites/davidshaywitz/2016/06/01/marc-andreessen-nails-challenge-of-applying-tech-to-medicine-the-idiosyncrasies-of-people/ Marc Andreessen Nails The Challenge Of Applying Tech To Medicine: The Idiosyncrasies Of PeopleTech VCs optimistic artificial intelligence can do many things -- but not tech vc; that, evidently, involves complicated human interactions.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/574f55d664aaf9337ca86c30Wed, 1 Jun 2016 21:52:00 +00002016-06-01T21:52:00ZTech VCs optimistic artificial intelligence can do many things -- but not tech vc; that, evidently, involves complicated human interactions.https://www.forbes.com/sites/davidshaywitz/2016/05/15/math-camp-where-silicon-valley-innovators-begin/ Math Camp: Where Silicon Valley Innovators BeginWhy so many Silicon Valley innovators first found refuge in math camp.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5738d244e4b0902e54d4795bSun, 15 May 2016 20:11:00 +00002016-05-15T20:11:00ZWhy so many Silicon Valley innovators first found refuge in math camp.https://www.forbes.com/sites/davidshaywitz/2016/04/10/from-one-old-guy-to-another-what-dan-lyons-misses-about-silicon-valley/ From One Old Guy To Another: What Dan Lyons Misses About Silicon Valley"Technology is the Trojan Horse for change" - Susannah Fox, CTO, HHSDavid Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/570af5d2e4b0876fd0e4eed5Mon, 11 Apr 2016 01:09:00 +00002016-04-11T01:09:00Z"Technology is the Trojan Horse for change" - Susannah Fox, CTO, HHShttps://www.forbes.com/sites/davidshaywitz/2016/04/04/the-vital-role-of-industry-in-crossing-the-translational-divide/ Academia And Industry Do Not Need To Be At Odds With Each OtherTurning science into medicines is an important and worthy challenge, pursued with passion, intelligence, and integrity by many physicians and scientists. New medicines do not fall easily and inevitably out of academic research, but require deliberate, painstaking development – and unreasonably resilient drug hunters able to cope with a staggeringly high failure rate.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5702ba6ee4b0876fd0e4cbbaMon, 4 Apr 2016 19:29:00 +00002016-04-04T19:29:00ZTurning science into medicines is an important and worthy challenge, pursued with passion, intelligence, and integrity by many physicians and scientists. New medicines do not fall easily and inevitably out of academic research, but require deliberate, painstaking development – and unreasonably resilient drug hunters able to cope with a staggeringly high failure rate.https://www.forbes.com/sites/davidshaywitz/2016/03/29/entrepreneurship-as-translation-why-a-rising-academic-physician-left-stanford-for-a-startup/ Entrepreneurship As Translation: Why A Rising Academic Physician Left Stanford For A StartupTranslation is complex in a way that’s difficult to fully appreciate and understand unless you are in the arena, as a participant, actively engaged in wrestling a difficult problem to the ground.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/56fb0928e4b0876fd0e4a5b1Tue, 29 Mar 2016 23:11:00 +00002016-03-29T23:11:00ZTranslation is complex in a way that’s difficult to fully appreciate and understand unless you are in the arena, as a participant, actively engaged in wrestling a difficult problem to the ground.https://www.forbes.com/sites/davidshaywitz/2016/03/18/precision-behavioral-interventions-based-on-revealed-preferences-key-to-population-health/ Precision Behavioral Interventions, Based On Revealed Preferences, Key To Population HealthImproving the health of populations may require customization of therapy – behavioral as well as molecular – to each individualDavid Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/56ec61cee4b063cb9d020b4cFri, 18 Mar 2016 20:48:00 +00002016-03-18T20:48:00ZImproving the health of populations may require customization of therapy – behavioral as well as molecular – to each individualhttps://www.forbes.com/sites/davidshaywitz/2016/03/14/lessons-from-la-jolla-the-complexity-of-patients-the-value-of-entrepreneurship/ Lessons From La Jolla: The Complexity of Patients, The Value Of Entrepreneurship“I take pride in teaching my students and trainees to start companies too, because it’s the only way I can scale." - Atul Butte, UCSFDavid Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/56e635dae4b063cb9d01ec54Mon, 14 Mar 2016 04:27:00 +00002016-03-14T04:27:00Z“I take pride in teaching my students and trainees to start companies too, because it’s the only way I can scale." - Atul Butte, UCSFhttps://www.forbes.com/sites/davidshaywitz/2016/03/08/as-ambry-ceo-demonstrates-patients-drive-data-sharing/ As Ambry CEO Demonstrates, Patients Drive Data SharingPatients recognize that it's in our enlightened self-interest to share health data.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/56df66cbe4b063cb9d01d525Wed, 9 Mar 2016 00:08:00 +00002016-03-09T00:08:00ZPatients recognize that it's in our enlightened self-interest to share health data.https://www.forbes.com/sites/davidshaywitz/2016/03/03/mathai-mammen-the-anti-shkreli-brings-heart-and-a-touch-of-vagelos-to-merck-rd/ Mathai Mammen, The Anti-Shkreli, Brings Heart And A Touch Of Vagelos To Merck R&DIn attracting Mathai to a senior role on their R&D team (exact title not yet available), Merck will be getting not only someone who is an experienced drug hunter, dedicated to good science and great talent, in the tradition of (and in a sense, groomed by) Roy Vagelos, but also a remarkably resilient and empathetic human being, someone who is neither an opportunistic businessman nor a detached scientist, but rather a highly attuned leader with a profound sense of loss and of life, and who wants to make new medicines because he’s determined to make a difference.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/56d85901e4b0d99cd21cfb82Thu, 3 Mar 2016 15:51:00 +00002016-03-03T15:51:00ZIn attracting Mathai to a senior role on their R&D team (exact title not yet available), Merck will be getting not only someone who is an experienced drug hunter, dedicated to good science and great talent, in the tradition of (and in a sense, groomed by) Roy Vagelos, but also a remarkably resilient and empathetic human being, someone who is neither an opportunistic businessman nor a detached scientist, but rather a highly attuned leader with a profound sense of loss and of life, and who wants to make new medicines because he’s determined to make a difference.https://www.forbes.com/sites/davidshaywitz/2016/01/24/do-we-really-want-to-separate-clinical-data-gathering-and-data-analysis/ Do We Really Want To Separate Clinical Data Gathering And Data Analysis?Is the activity of data analysis properly viewed as separate, and separable from the activity of data gathering?David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/56a4f33be4b08dc4ac80b72aSun, 24 Jan 2016 15:55:00 +00002016-01-24T15:55:00ZIs the activity of data analysis properly viewed as separate, and separable from the activity of data gathering?https://www.forbes.com/sites/davidshaywitz/2016/01/22/biden-cancer-project-an-opportunity-to-implement-data-sharing-incentives/ Biden Cancer Project: An Opportunity To Implement Data Sharing IncentivesIf our goal is motivating researchers to share data more extensively, I’m not sure twitter shaming is the best way to get us there. Rather, we should contemplate, in a thoughtful and grounded fashion, the real-world factors that influence academic investigators, and look for ways to adjust incentives accordingly.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/56a2cf7ee4b08dc4ac80a54eSat, 23 Jan 2016 01:10:00 +00002016-01-23T01:10:00ZIf our goal is motivating researchers to share data more extensively, I’m not sure twitter shaming is the best way to get us there. Rather, we should contemplate, in a thoughtful and grounded fashion, the real-world factors that influence academic investigators, and look for ways to adjust incentives accordingly.https://www.forbes.com/sites/davidshaywitz/2016/01/21/data-scientists-research-parasites/ Data Scientists = Research Parasites?But until and unless we come to grips with the gritty, human, competitive reasons why data aren’t shared, we’re headed to a future of righteous proclamations – and little data movement.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/56a1a508e4b08dc4ac80984aFri, 22 Jan 2016 03:54:00 +00002016-01-22T03:54:00ZBut until and unless we come to grips with the gritty, human, competitive reasons why data aren’t shared, we’re headed to a future of righteous proclamations – and little data movement.https://www.forbes.com/sites/davidshaywitz/2016/01/18/the-last-best-chance-to-achieve-interoperability/ The Last, Best Chance To Achieve Interoperability?"Interoperability has always been a political/cultural problem, not a technical one, and without additional political support FHIR will die on the vine like everything before it. To be successful, it needs ongoing, active support from both vendors and health systems. We need both missile keys-- just one or the other is not sufficient." - Ed Park, COO, athenahealthDavid Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/569d2b64e4b08dc4ac8073a3Tue, 19 Jan 2016 03:48:00 +00002016-01-19T03:48:00Z"Interoperability has always been a political/cultural problem, not a technical one, and without additional political support FHIR will die on the vine like everything before it. To be successful, it needs ongoing, active support from both vendors and health systems. We need both missile keys-- just one or the other is not sufficient." - Ed Park, COO, athenahealthhttps://www.forbes.com/sites/davidshaywitz/2015/12/18/the-science-or-lack-of-it-behind-genetic-tests-offered-in-the-workplace/ The Science -- Or Lack Of It -- Behind Genetic Tests Offered In The WorkplaceGenetic testing for cancer risk can make sense, though there are important caveats; genetic testing to inform food and fitness recommendations, in contrast, seems like quackery.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5673a521e4b08dc4ac7fb595Fri, 18 Dec 2015 06:45:00 +00002015-12-18T06:45:00ZGenetic testing for cancer risk can make sense, though there are important caveats; genetic testing to inform food and fitness recommendations, in contrast, seems like quackery.https://www.forbes.com/sites/davidshaywitz/2015/12/14/podcasts-and-people-for-healthcare-entrepreneurs-to-follow-in-2016/ Podcasts And People For Healthcare Entrepreneurs To Follow In 2016Podcasts and people for healthcare entrepreneurs to keep an eye on in 2016.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/566ec3bde4b03572b500ec46Mon, 14 Dec 2015 13:59:00 +00002015-12-14T13:59:00ZPodcasts and people for healthcare entrepreneurs to keep an eye on in 2016.https://www.forbes.com/sites/davidshaywitz/2015/12/14/a-centrist-perspective-on-healthcare-consumerism/ A Nuanced Take On Healthcare ConsumerismGiven the natural tendency for the shrillest and most extreme views to rise above the clatter and define the terms of the discussion, I’ve long wished for my own Woody Allen-Marshall McLuhan moment, where I could introduce into the healthcare conversation an articulate expert who could cut through the posturing and provide the dialog the grounding it deserves.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/566e2002e4b03572b500eb44Mon, 14 Dec 2015 11:00:00 +00002015-12-14T11:00:00ZGiven the natural tendency for the shrillest and most extreme views to rise above the clatter and define the terms of the discussion, I’ve long wished for my own Woody Allen-Marshall McLuhan moment, where I could introduce into the healthcare conversation an articulate expert who could cut through the posturing and provide the dialog the grounding it deserves.https://www.forbes.com/sites/davidshaywitz/2015/12/05/eight-themes-from-the-corner-of-interoperability-and-precision-medicine/ Eight Themes From The Corner Of Interoperability And Precision MedicineScience is hard, biology is complex, disease is relentless – and neither Presidential proclamations nor transformative technologies alter these fundamental realities. The intrinsic worthiness, even nobility, of our collective ambition to understand and treat disease in a more individualized fashion doesn’t grant us the ability to achieve and deliver this.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/56635273e4b0875cdd53e7afSat, 5 Dec 2015 21:53:00 +00002015-12-05T21:53:00ZScience is hard, biology is complex, disease is relentless – and neither Presidential proclamations nor transformative technologies alter these fundamental realities. The intrinsic worthiness, even nobility, of our collective ambition to understand and treat disease in a more individualized fashion doesn’t grant us the ability to achieve and deliver this.innovation-rxhttps://www.forbes.com/sites/davidshaywitz/2015/11/24/from-unmentionables-to-the-voice-of-the-patient-lessons-from-a-year-of-digital-health-podcasts/ From Unmentionables To The Voice Of The Patient: Lessons From A Year Of Digital Health PodcastsThese remains very early days for digital health, and after a period of extravagant expectation (say two years ago) and inevitable disillusionment (much of this year), I think we’re slowly ascending the so-called slope of enlightenment.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5654de2fe4b0875cdd53b29eTue, 24 Nov 2015 22:16:00 +00002015-11-24T22:16:00ZThese remains very early days for digital health, and after a period of extravagant expectation (say two years ago) and inevitable disillusionment (much of this year), I think we’re slowly ascending the so-called slope of enlightenment.https://www.forbes.com/sites/davidshaywitz/2015/11/23/where-is-healthcares-breakout-data-science-company/ Where Is Healthcare's Breakout Data Science Company?It’s easier to get someone to click on an ad than to avoid a donut. Even the most compelling user interface may not matter very much once someone steps away from the keyboard, or puts their smartphone back in their pocket.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5653cd5fe4b0f08a2dcd3517Tue, 24 Nov 2015 02:52:00 +00002015-11-24T02:52:00ZIt’s easier to get someone to click on an ad than to avoid a donut. Even the most compelling user interface may not matter very much once someone steps away from the keyboard, or puts their smartphone back in their pocket.https://www.forbes.com/sites/davidshaywitz/2015/11/20/the-harmful-mutations-that-werent/ The Harmful Mutations That Weren'tWhat this study shows, however, is that we need to be extremely careful before concluding that a defect in a particular gene is likely associated with a given -- generally bad -- consequence.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/564f783de4b0f08a2dcd268cFri, 20 Nov 2015 19:54:00 +00002015-11-20T19:54:00ZWhat this study shows, however, is that we need to be extremely careful before concluding that a defect in a particular gene is likely associated with a given -- generally bad -- consequence.healthcare2025https://www.forbes.com/sites/davidshaywitz/2015/11/01/why-does-the-new-york-times-say-mr-carson-but-dr-kocher/ Why Does The New York Times Say 'Mr. Carson' But 'Dr. Kocher?'When does an M.D. lose the right to be considered a doctor?David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5636243ce4b0375e492cc6c2Sun, 1 Nov 2015 14:44:00 +00002015-11-01T14:44:00ZWhen does an M.D. lose the right to be considered a doctor?https://www.forbes.com/sites/davidshaywitz/2015/10/31/first-we-devalued-doctors-now-technology-struggles-to-replace-them/ First, We Devalued Doctors; Now, Technology Struggles To Replace ThemWe’ve industrialized the physician-doctor encounter – the process and the paperwork -- but eviscerated the human relationship; it’s value, unable to translate easily to an excel spreadsheet, was discounted and dismissed.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/56346fd7e4b0375e492cc23eSat, 31 Oct 2015 08:00:00 +00002015-10-31T08:00:00ZWe’ve industrialized the physician-doctor encounter – the process and the paperwork -- but eviscerated the human relationship; it’s value, unable to translate easily to an excel spreadsheet, was discounted and dismissed.https://www.forbes.com/sites/davidshaywitz/2015/10/30/new-diabetes-study-shows-how-big-data-might-drive-precision-medicine/ New Diabetes Study Shows How Big Data Might Drive Precision MedicineTo this point, it’s largely been an article of faith that such rich integrated datasets would be useful and clinically important. The hope this paper represents is that perhaps we’re finally closing in on a tipping point, or a coalescence point, when we’ll at last see a compelling return on all the upfront effort involved in creating such a rich datasets, and also start to see which sorts of data collisions generate the most impactful results.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/563418a7e4b0375e492cc1b0Sat, 31 Oct 2015 01:38:00 +00002015-10-31T01:38:00ZTo this point, it’s largely been an article of faith that such rich integrated datasets would be useful and clinically important. The hope this paper represents is that perhaps we’re finally closing in on a tipping point, or a coalescence point, when we’ll at last see a compelling return on all the upfront effort involved in creating such a rich datasets, and also start to see which sorts of data collisions generate the most impactful results.innovation-rxhttps://www.forbes.com/sites/davidshaywitz/2015/10/05/rapid-data-sharing-can-yield-better-solutions-but-may-overlook-the-best-ones/ How Too Much Knowledge Sharing Can Suppress InnovationThe real challenge, it seems, for those who manage innovation, and for those like Josh Sommer (and really, all of us) who have a stake in the outcome, is figuring out how, on the one hand, to leverage the demonstrated power of data sharing to incrementally improve and rapidly refine solutions while, on the other hand, not losing sight of the the benefits of independent research, work that might be slower, but, in reducing the impact of groupthink, could yield answers that are more original, profound, and impactful.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/56121158e4b08c2312f34365Mon, 5 Oct 2015 12:00:00 +00002015-10-05T12:00:00ZThe real challenge, it seems, for those who manage innovation, and for those like Josh Sommer (and really, all of us) who have a stake in the outcome, is figuring out how, on the one hand, to leverage the demonstrated power of data sharing to incrementally improve and rapidly refine solutions while, on the other hand, not losing sight of the the benefits of independent research, work that might be slower, but, in reducing the impact of groupthink, could yield answers that are more original, profound, and impactful.https://www.forbes.com/sites/davidshaywitz/2015/09/29/three-pharmas-highlight-contrasting-approaches-to-product-innovation/ Three Pharmas Highlight Contrasting Approaches To Product Innovationt will be interesting to see (1) if Regeneron’s investment in basic science yields the bumper crop of novel medications Yancopoulos clearly anticipates; (2) if Allergan continues to prove as adept in identifying, acquiring, and developing truly innovative early-stage compounds as company leadership believes it will be; and (3) if Teva’s plan to use emerging technologies to create compelling solutions around existing drugs proves a viable strategy.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/560b25f8e4b08c2312f31305Wed, 30 Sep 2015 00:27:00 +00002015-09-30T00:27:00Zt will be interesting to see (1) if Regeneron’s investment in basic science yields the bumper crop of novel medications Yancopoulos clearly anticipates; (2) if Allergan continues to prove as adept in identifying, acquiring, and developing truly innovative early-stage compounds as company leadership believes it will be; and (3) if Teva’s plan to use emerging technologies to create compelling solutions around existing drugs proves a viable strategy.https://www.forbes.com/sites/davidshaywitz/2015/09/28/precision-medicine-seeking-impact-needing-champions/ Precision Medicine: Seeking Impact, Needing ChampionsWhile the promise of precision medicine may reflect advances in technology, realization of this potential will require impassioned champions.David Shaywitz, ContributorDavid Shaywitz, Contributorhttps://www.forbes.com/sites/davidshaywitz/5609ce57e4b08c2312f30a76Tue, 29 Sep 2015 00:00:00 +00002015-09-29T00:00:00ZWhile the promise of precision medicine may reflect advances in technology, realization of this potential will require impassioned champions.